earn report chang price
phunk heart
risk toler current level
increas underli top-line revenu guidanc
bp full year ep guidanc mid-point
underli us tavr grew exclud impact lower
royalti revenu much better suggest initi
headlin underl sequenti growth
anticip inventori stock relat benefit
anticip come back guidanc impli guidanc
rais driven clean fundament
rais critic revenu outlook high end rang prior
ou tavr revenu growth impli europ like high
singl digit rang japan mid teen
gross margin miss street estim
ep guidanc mid-point came lower street
note slight delay harpoon mitral repair program examin
case advers event undergo root caus analysi
ew alway keep us toe given heighten scrutini
compani face sequenti tavr growth number ye
sequenti us tavr number mm look like headlin miss
vs st note us impact mm lower royalti
incom ex underli us tavr grew yoy
qoq in-lin st estim possibl whisper
expect outsid number
stood us slowdown eu given bp share
loss understand acknowledg st concern
headlin miss come lower tax drive
ep beat stock reaction aftermarket write
seem exagger us peel back onion layer easi
forget ew grew revenu organ exclud
royalti impact would exclud bp day
impact back confid outlook compani
also rais underli top-line growth outlook rang
ep guid high end impli yoy growth share current
trade ep histor trough
multipl ew share potenti risk indic expans
set catalyst would buyer ew tomorrow
weak see risk reward skew upsid
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
chart ponder upon ew share trade near trough level aftermarket base price-to-earnings
continu next page
total sale high end mm rang underli growth includ consolid fx tailwind
transcath heart valv therapi high end mm denot underli sale growth
high end rang
surgic heart valv therapi high end mm denot underli sale growth
critic high end mm denot underli sale growth
gross margin sale exclud special item
sg sale driven euro/usd strength personnel-rel expens
 sale exclud special item
tax rate stock base comp influenc go forward rate tax reform benefit realiz tail
free high end mm
consign inventori convers complet end estim mm mm
mm minimum royalti year lower vs cadenc front load
tmtt sale ramp throughout year approx million full year
continu next page
minim amount sale quarter begun target introduct posit valv specif eu center
enrol expect single-arm trial patient one-year endpoint also enrol patient
bicuspid sub studi increas spend
data expect march fda approv low-risk indic later year
transcathet mitral tricuspid program expect sale mm fy
mm sale
encourag high procedur success rate inventori may constrain throughout
ce mark enrol on-track eu launch plan
track initi us trial later
sapien ultra system expect receiv ce mark
small clinic trial supplement eu regulatori submiss
expect complet enrol patient quarter
intuiti elit continu strong us
inspiri resilia japan launch expect year pend reimburs approv
harpoon integr signific progress made target midyear eu launch
complic treat earli clinic expect materi impact shvt sale
led primarili hemospher strong region perform asia pacif
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin april et
analyst vijay kumar primarili respons prepar research report attest follow view opinion
render research report reflect person view subject compani issuer part research
analyst compens directli relat specif recommend view research report
report approv and/or distribut evercor group llc evercor group licens broker-deal regul
industri regulatori author finra intern strategi invest group uk limit isi uk authoris regul
unit kingdom financi conduct author institut sale trade research busi evercor group isi
uk collect oper global market brand name evercor isi evercor isi evercor group isi uk subsidiari
evercor partner inc evercor partner trademark logo servic mark shown report regist trademark
analyst associ respons prepar report receiv compens base variou factor includ evercor partner
total revenu portion gener affili invest bank transact evercor isi seek updat research
appropri variou regul may prevent happen certain instanc asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgment
evercor isi gener prohibit analyst associ member household maintain financi interest secur
compani analyst area coverag except polici requir specif approv member complianc
depart ownership subject complianc applic regul disclosur evercor isi also prohibit analyst associ
